Sarepta’s Duchenne gene therapy wins OK; FDA spurns NASH drug; Eli Lilly buys DICE for $2.4B; The new antitrust landscape; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The Endpoints…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks